Clinical trial
Atrasentan in Treating Patients With Prostate Cancer
NCT00046943 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00046943 |
|---|---|
| Title | Atrasentan in Treating Patients With Prostate Cancer |
| Official title | A Phase III Extension Study to Evaluate the Safety of 10 mg Atrasentan in Men With Hormone-Refractory Prostate Cancer |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | atrasentan hydrochloride |
| Start date | Sep 1, 2002 |
| Primary completion | Jun 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 21, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: